ADC Therapeutics (ADCT) Return on Capital Employed (2024 - 2026)
ADC Therapeutics' (ADCT) quarterly Return on Capital Employed came in at 53.75% in Q1 2026, down 84.0% year-on-year from 335.91% in Q1 2025, and up 5.9% quarter-over-quarter from 57.12% in Q3 2025.
ADC Therapeutics (ADCT) Return on Capital Employed (2024 - 2026) Analysis & Trends
ADC Therapeutics has disclosed Return on Capital Employed across 3 years of filings, most recently posting 53.75% for Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 51.73% |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -107.40% |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -50.43% |
| 10 | ADC Therapeutics | 167.24 Mn | -63.76 Mn | 7.33 Mn | -53.75% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -53.75% |
| Sep 30, 2025 | -57.12% |
| Jun 30, 2025 | -59.03% |
| Mar 31, 2025 | -52.90% |
| Sep 30, 2024 | -45.90% |
| Jun 30, 2024 | -49.05% |